UA79650C2 - Use of docosahexaenoic acid as an active substance for treatment of lipodystrophy - Google Patents

Use of docosahexaenoic acid as an active substance for treatment of lipodystrophy Download PDF

Info

Publication number
UA79650C2
UA79650C2 UAA200505318A UA2005005318A UA79650C2 UA 79650 C2 UA79650 C2 UA 79650C2 UA A200505318 A UAA200505318 A UA A200505318A UA 2005005318 A UA2005005318 A UA 2005005318A UA 79650 C2 UA79650 C2 UA 79650C2
Authority
UA
Ukraine
Prior art keywords
use according
docosahexaenoic acid
lipodystrophy
treatment
extract
Prior art date
Application number
UAA200505318A
Other languages
English (en)
Ukrainian (uk)
Inventor
Pedrol Juan Carlos Domingo
Pedrol Pere Domingo
Original Assignee
Proyecto Empresarial Brudy Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Empresarial Brudy Sl filed Critical Proyecto Empresarial Brudy Sl
Publication of UA79650C2 publication Critical patent/UA79650C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UAA200505318A 2002-12-05 2003-01-12 Use of docosahexaenoic acid as an active substance for treatment of lipodystrophy UA79650C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200202963A ES2209658B1 (es) 2002-12-05 2002-12-05 Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
PCT/IB2003/005673 WO2004050077A1 (en) 2002-12-05 2003-12-01 Use of docosahexanoic acid as active substance for the treatment of lipodystrophy

Publications (1)

Publication Number Publication Date
UA79650C2 true UA79650C2 (en) 2007-07-10

Family

ID=32405973

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200505318A UA79650C2 (en) 2002-12-05 2003-01-12 Use of docosahexaenoic acid as an active substance for treatment of lipodystrophy

Country Status (24)

Country Link
US (1) US8202906B2 (de)
EP (1) EP1585513B1 (de)
JP (1) JP2006511514A (de)
KR (1) KR100906086B1 (de)
CN (1) CN100355421C (de)
AT (1) ATE326959T1 (de)
AU (1) AU2003302679B2 (de)
BR (1) BR0316973A (de)
CA (1) CA2506993C (de)
CY (1) CY1105205T1 (de)
DE (1) DE60305534T2 (de)
DK (1) DK1585513T3 (de)
EA (1) EA009711B1 (de)
ES (2) ES2209658B1 (de)
IL (1) IL168766A (de)
IS (1) IS2384B (de)
MX (1) MXPA05005911A (de)
NO (1) NO20052960L (de)
NZ (1) NZ540262A (de)
PL (1) PL377563A1 (de)
PT (1) PT1585513E (de)
UA (1) UA79650C2 (de)
WO (1) WO2004050077A1 (de)
ZA (1) ZA200503872B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1656934A1 (de) * 2004-11-12 2006-05-17 Cognis IP Management GmbH Verwendung von physiologisch aktiven Fettsäuren zur Behandlung von Lipodystrophie
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
JP5207342B2 (ja) * 2007-02-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
SG10201408158SA (en) 2008-01-03 2015-03-30 Univ Aix Marseille Composition and methods used during anti-hiv treatment
CN110339187B (zh) * 2019-07-30 2021-12-14 中国医学科学院病原生物学研究所 缓解寨卡病毒感染相关的新生儿小头症的药物
CN116585216A (zh) * 2022-05-16 2023-08-15 上海中翊日化有限公司 一种含有羟基频哪酮视黄酸酯(hpr)并降低光损伤及炎症的抗衰组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3901048A1 (de) * 1989-01-14 1990-07-19 Chimicasa Gmbh Antikachectikum
US5089268A (en) * 1990-05-02 1992-02-18 Katz David P Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
JP3092180B2 (ja) * 1991-02-27 2000-09-25 日本油脂株式会社 低密度リポ蛋白受容体活性化剤
GB9116054D0 (en) * 1991-07-24 1991-09-11 Efamol Holdings Preparation of fatty acid medicaments
JPH0923817A (ja) * 1995-07-07 1997-01-28 Nisshin Oil Mills Ltd:The 油脂含有飲食物
FR2749133A1 (fr) 1996-06-04 1997-12-05 Pierre Moreau Obtention d'oeufs specifiquement enrichis en acide cervonique (acide docosahexaenoique ou dha). applications alimentaires, therapeutiques et industrielles de ces oeufs et de leurs extraits lipidiques
FR2790758A1 (fr) * 1999-03-09 2000-09-15 Commissariat Energie Atomique Solubilisation d'acides gras polyinsatures et de leurs derives par formation de complexes d'inclusion avec une cyclodextrine et leur utilisation dans des compositions pharmaceutiques, cosmetiques ou alimentaires
CA2290885A1 (fr) * 1999-12-02 2001-06-02 Universite De Sherbrooke Methode pour la transformation des tissus du loup marin
ATE384518T1 (de) * 2000-01-31 2008-02-15 Haerting S A Zusammensetzungen enthaltend phytosterol- und policosanolester von fettsäuren zur herabsetzung des cholesterol- und triglyceridspiegels
JP2001314170A (ja) * 2000-05-09 2001-11-13 Toyo Shinyaku:Kk 麦若葉由来の素材を含む抗コレステロール食品
ES2246769T3 (es) * 2000-05-22 2006-03-01 Pro Aparts - Investimentos E Consultoria Lda Composicion de acidos grasos que contiene al menos 80% en peso de epa y dha o sus derivados y su uso farmaceutico.
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia

Also Published As

Publication number Publication date
DE60305534T2 (de) 2007-05-16
JP2006511514A (ja) 2006-04-06
KR100906086B1 (ko) 2009-07-06
US8202906B2 (en) 2012-06-19
IS2384B (is) 2008-07-15
DK1585513T3 (da) 2006-09-18
WO2004050077A1 (en) 2004-06-17
ES2209658B1 (es) 2005-10-01
IS7912A (is) 2005-06-23
PT1585513E (pt) 2006-10-31
BR0316973A (pt) 2005-10-25
CA2506993C (en) 2010-04-13
AU2003302679B2 (en) 2009-01-15
CA2506993A1 (en) 2004-06-17
DE60305534D1 (de) 2006-06-29
MXPA05005911A (es) 2005-08-29
ES2265607T3 (es) 2007-02-16
KR20050085313A (ko) 2005-08-29
PL377563A1 (pl) 2006-02-06
CN100355421C (zh) 2007-12-19
EA009711B1 (ru) 2008-02-28
ES2209658A1 (es) 2004-06-16
US20060178436A1 (en) 2006-08-10
ZA200503872B (en) 2006-08-30
CY1105205T1 (el) 2010-03-03
IL168766A (en) 2009-11-18
EA200500765A1 (ru) 2005-12-29
NO20052960L (no) 2005-06-16
EP1585513A1 (de) 2005-10-19
NZ540262A (en) 2006-11-30
EP1585513B1 (de) 2006-05-24
ATE326959T1 (de) 2006-06-15
CN1720039A (zh) 2006-01-11
AU2003302679A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
JP4151853B2 (ja) エイコサペンタエン酸および／またはステアリドン酸を含む治療用薬剤
JP4570563B2 (ja) リバビリン／インターフェロン併用療法の副作用軽減剤
NO328797B1 (no) Anvendelse av essensielle fettsyrer inneholdende en blanding av eikosapentaensyreetylester (EPA) og docosaheksaensyreetylester (DHA) for fremstilling av et medikament nyttig ved forebyggelse av dodsfall hos en pasient som har hatt et hjerteinfarkt.
KR100906086B1 (ko) 활성 물질로서 도코사헥사엔산을 포함하는 지방이상증 치료를 위한 약제학적 조성물
TW200410683A (en) Medicament for preventing and/or treating peripheral neuropathies
AU2016402338A1 (en) Combinational compositions and methods of use thereof
JP5952556B2 (ja) 褥瘡治療剤
US20080161604A1 (en) Acetyl L-Carnitine For Preventing Painful Peripheral Diabetic Neuropathy
US8952059B2 (en) Acetyl L-carnitine for the preparation of a medicament for the prevention of painful peripheral neuropathy in patients with type 2 diabetes
JP2024526939A5 (de)
JP5710150B2 (ja) 潜伏性感染疾患の再発抑制剤
US20200085774A1 (en) Omega-3 Fatty Acid Composition for Preventing and/or Treating Cachexia
CN110013474A (zh) 非诺贝特的新用途以及针对新用途的药物
US20170296499A1 (en) Combinational compositions and methods of use thereof
EP1874288B1 (de) Acetyl l-carnitin zur vorbeugung schmerzhafter periphärer diabetischer neuropathie
JP2010090087A (ja) 潜伏性感染疾患の再発抑制剤
WO2025075519A1 (en) Preparation and its application in atopic dermatitis in children
CN120605308A (zh) 珍宝丸在制备用于预防脑卒中的药物中的应用
AU2016390920A1 (en) New use of isoquinoline derivatives for diabetic wound healing
CN118453565A (zh) 癸酸单甘油酯在制备肥胖症治疗药物或功能食品中的应用
RU2021111065A (ru) Композиции и способы с использованием по меньшей мере одного глицина или его производного, по меньшей мере одного n-ацетилцистеина или его производного и по меньшей мере одного никотинамидрибозида или предшественника nad+